Agile Therapeutics Inc (NASDAQ:AGRX) Forecasted to Post Q3 2019 Earnings of ($0.07) Per Share

Agile Therapeutics Inc (NASDAQ:AGRX) – Research analysts at Oppenheimer increased their Q3 2019 EPS estimates for Agile Therapeutics in a note issued to investors on Monday, August 5th, according to Zacks Investment Research. Oppenheimer analyst L. Gershell now anticipates that the specialty pharmaceutical company will earn ($0.07) per share for the quarter, up from their prior forecast of ($0.09). Oppenheimer has a “Outperform” rating and a $5.00 price target on the stock. Oppenheimer also issued estimates for Agile Therapeutics’ Q4 2019 earnings at ($0.11) EPS, FY2019 earnings at ($0.38) EPS and FY2020 earnings at $0.00 EPS.

Agile Therapeutics (NASDAQ:AGRX) last issued its quarterly earnings results on Thursday, August 1st. The specialty pharmaceutical company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03.

Several other research analysts have also recently weighed in on AGRX. Zacks Investment Research raised Agile Therapeutics from a “hold” rating to a “strong-buy” rating and set a $1.25 target price for the company in a research note on Tuesday, August 6th. Maxim Group set a $3.00 price target on Agile Therapeutics and gave the company a “buy” rating in a research report on Monday, June 10th. Finally, ValuEngine lowered Agile Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, August 1st. One analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $3.45.

Shares of AGRX stock opened at $1.11 on Thursday. The stock has a 50-day simple moving average of $1.28 and a 200 day simple moving average of $1.30. Agile Therapeutics has a fifty-two week low of $0.25 and a fifty-two week high of $1.70. The stock has a market capitalization of $51.49 million, a P/E ratio of -1.91 and a beta of 0.54.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in shares of Agile Therapeutics by 129.8% during the 2nd quarter. Vanguard Group Inc. now owns 1,732,648 shares of the specialty pharmaceutical company’s stock worth $2,530,000 after purchasing an additional 978,672 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Agile Therapeutics by 5.6% during the 2nd quarter. Renaissance Technologies LLC now owns 2,254,180 shares of the specialty pharmaceutical company’s stock worth $3,291,000 after purchasing an additional 120,403 shares in the last quarter. Acadian Asset Management LLC raised its stake in shares of Agile Therapeutics by 33.3% during the 1st quarter. Acadian Asset Management LLC now owns 417,269 shares of the specialty pharmaceutical company’s stock worth $630,000 after purchasing an additional 104,222 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Agile Therapeutics by 2,219.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 76,538 shares of the specialty pharmaceutical company’s stock worth $108,000 after purchasing an additional 73,238 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Agile Therapeutics by 24.0% during the 4th quarter. Geode Capital Management LLC now owns 230,496 shares of the specialty pharmaceutical company’s stock worth $132,000 after purchasing an additional 44,639 shares in the last quarter. Hedge funds and other institutional investors own 41.41% of the company’s stock.

In other Agile Therapeutics news, CEO Alfred Altomari acquired 20,000 shares of the firm’s stock in a transaction on Monday, June 10th. The stock was purchased at an average cost of $1.27 per share, for a total transaction of $25,400.00. Following the transaction, the chief executive officer now owns 258,568 shares of the company’s stock, valued at approximately $328,381.36. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 8.50% of the company’s stock.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials.

Featured Story: Fibonacci Channel

Get a free copy of the Zacks research report on Agile Therapeutics (AGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.